James Wilson resigns from Solid Biosciences' board

Gene therapy pioneer James Wilson resigned from the scientific advisory board at Solid Biosciences LLC (Cambridge, Mass.), according to an SEC filing. The filing said Wilson cited "emerging concerns about the possible risks of high systemic dosing of AAV [adeno-associated virus]." Wilson did not respond to inquiries in time for publication. Solid Biosciences' lead candidate SGT-001 is a gene therapy delivered via an AAV vector.

Wilson is a professor and director of the gene therapy program at the University of Pennsylvania as well as the scientific founder of RegenxBio Inc. (NASDAQ:RGNX), which is developing AAV viral vector therapies on its NAV gene delivery platform. ...